Overall survival, costs, and healthcare resource use by line of therapy in Medicare patients with newly diagnosed metastatic urothelial carcinoma-Reference-Cited by-同舟云学术

Overall survival, costs, and healthcare resource use by line of therapy in Medicare patients with newly diagnosed metastatic urothelial carcinoma

Published:2019-03-25 Issue:7 Volume:22 Page:662-670
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Aly Abdalla¹,Johnson Courtney¹,Yang Shuo²,Botteman Marc F.¹^ORCID,Rao Sumati²,Hussain Arif³

Affiliation:

1. Real-World Evidence and Data Analytics, Pharmerit International, Bethesda, MD, USA;

2. US Health Economics Outcomes Research, Bristol-Myers Squibb, Princeton, NJ, USA;

3. Hormone Responsive Cancers Program, University of Maryland Greenebaum Comprehensive Cancer Center and Baltimore VA Medical Center, Baltimore, MD, USA

Funder

Bristol-Myers Squibb

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://tandfonline.com/doi/pdf/10.1080/13696998.2019.1591424

Reference30 articles.

1. Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends

2. The present and future burden of urinary bladder cancer in the world

3. Cancer statistics, 2017

4. Management of metastatic urothelial cancer: the role of surgery as an adjunct to chemotherapy

5. Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Factors associated with receipt of systemic anticancer treatment for locally advanced or metastatic urothelial carcinoma in England: a population-based study;Urologic Oncology: Seminars and Original Investigations;2024-07

2. Treatment Patterns and Survival Outcomes Before and After Access to Immune Checkpoint Inhibitors for Patients With Metastatic Urothelial Carcinoma: A Single-Center Retrospective Study From 2004 to 2021;Clinical Genitourinary Cancer;2024-06

3. Treatment Patterns and Attrition With Lines of Therapy for Advanced Urothelial Carcinoma in the US;JAMA Network Open;2024-05-02

4. Treatment patterns and clinical outcomes in metastatic urothelial carcinoma: a German retrospective real-world analysis;Future Oncology;2024-04-22

5. Healthcare resource utilization and associated costs in patients with metastatic urothelial carcinoma: a real-world analysis using German claims data;Journal of Medical Economics;2024-04-19